(Boston Orange摘譯) 麻州政府和麻州生命科學中心（MLSC）週四宣佈，將撥發約2,990萬美元稅務優惠給33家生命科學公司，估計可為麻州帶來1,519個新職位。
麻州州長Maura Healey宣佈給生命科學業3000萬美元抵稅優惠。
（麻州政府提供）
MLSC的稅務優惠計畫旨在強化麻州在生命科學研發、商業化及製造領域的全球領先地位。麻州州長奚莉（Maura Healey）今（12）日在劍橋市Lila Sciences公司宣佈這消息，強調投資對推動創新及人才的重要性。
奚莉州長表示，「世界看好麻州的生命科學未來，因為這裡創新研究、卓越人才與公私合作夥伴關係匯聚，推動顯著進展。透過MLSC稅務優惠計畫，我們正創造新職位，確保下一代科學突破誕生於此」。
麻州副州長Kim Driscoll也指出，這些獲獎助公司對經濟及全球健康都有貢獻。
MLSC還公佈，將啟動新一輪稅務優惠計畫，競爭性分配「麻州領先法案」法定上限4,000萬美元中，剩餘的1,010萬美元。申請期為2025年6月12日至7月16日下午5點，旨在支持2025年創造的淨新增職位。
麻州經濟發展廳代理廳長Ashley Stolba強調，該計畫對於吸引與留住頂尖人才至關重要。
值得注意的是，本次33家獲獎公司中，有18家將擴展至波士頓及劍橋以外地區，佔新職位承諾的48%，顯示州政府致力於全州均衡發展。
MLSC稅務優惠計畫自成立以來，已促成逾19,800個職位，鞏固麻州作為生命科學產業發展沃土的聲譽。獲獎助公司涵蓋藥物研發、醫療設備、診斷及製造等多元領域。
Lila Sciences共同創辦人兼執行長Geoffrey von Maltzahn表示，MLSC的支持推動了公司以AI優先方式轉型研發。專長於胸腺免疫療法的Thymmune Therapeutics創辦人兼執行長Ｓtan Wang則感謝州長與MLSC對就業與創新的投資。
該計畫由MLSC與麻州稅務局共同管理，確保嚴格監督。獲獎者需在三年內履行職位承諾，並定期提交報告。
Healey-Driscoll Administration Announces Tax Incentives to Create More Than 1,500 Life Sciences Jobs
Massachusetts Life Science Center awards nearly $30 million to 33 life sciences companies
CAMBRIDGE - Today, the Healey-Driscoll Administration and the Massachusetts Life Sciences Center (MLSC) announced $29.9 million in tax incentive awards to 33 life sciences companies. The awards, provided through the MLSC’s Tax Incentive Program, are expected to create 1,519 new life sciences industry jobs in Massachusetts. Governor Maura Healey joined MLSC President and CEO Kirk Taylor, MD, and state and local officials to announce the awards at Lila Sciences in Cambridge.
The Governor also announced a new competitive round of the tax incentive program. To fully maximize the new $40 million statutory cap in the Mass Leads Act, this round seeks to competitively award the remaining $10.1 million available for this year.
“The world looks to Massachusetts for the future of life sciences because we have built an ecosystem where innovative research, exceptional talent and public-private partnerships come together to drive significant progress,” said Governor Maura Healey. “With impactful investments like MLSC’s Tax Incentive Program, we are creating new jobs and ensuring that the next generation of scientific breakthroughs are being developed right here in our state.”
“This year’s tax incentive awardees are advancing scientific innovation, strengthening our economy and improving lives across the globe with groundbreaking work,” said Lieutenant Governor Kim Driscoll.“Their successes area shining example of why Massachusetts continues to lead the nation in life sciences.”
The MLSC Tax Incentive Program is offered to companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts, and provides incentives to companies of all sizes looking to expand their efforts by creating new, long-term jobs in the state.
“It is more important than ever for Massachusetts to support the life sciences ecosystem,” said Interim Economic Development Secretary Ashley Stolba, who serves as Co-Chair of the MLSC’s Board of Directors. “In this state, we're committed to ensuring that companies looking to expand have access to our top talent, and the tax incentive program is an important tool allowing us to continue to grow our ecosystem. The Mass Leads Act sharpened this tool and elevated its competitiveness.”
“Growing Massachusetts’ life sciences companies directly benefits our state’s workforce and economy,” said Administration and Finance Secretary Matthew J. Gorzkowicz, who serves as Co-Chair of the MLSC’s Board of Directors. “This commitment keeps Massachusetts competitive and allows our communities to thrive.”
Out of the 33 companies receiving tax incentive awards, 18 companies, accounting for 48 percent of the new jobs, are expanding in communities outside of Boston and Cambridge. Through this program, life sciences companies have committed to the creation of more than 19,800 jobs since the MLSC’s inception.
“Supporting job creation at innovative companies of all sizes is vital to strengthening Massachusetts’ position as the nation's leader in life sciences," said MLSC President and CEO Kirk Taylor, M.D. “The commitment of this year’s awardees is an inspiring demonstration of the Commonwealth’s shared dedication to advancing groundbreaking research and improving patients’ lives across the globe.”
“We are fortunate to be able to attract many of the brightest minds in AI and science on our mission to build scientific superintelligence,” said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Lila Sciences and General Partner, Flagship Pioneering. “Our commitment to add at least 100 new jobs here in Massachusetts is just the start. The MLSC’s support fuels continued momentum as Lila Sciences aims to transform R&D with an AI-first approach to life, chemistry, and materials science innovation.”
Last November, Governor Maura Healey signed the Mass Leads Act, an economic development bill building on the success of the state’s renowned life sciences sector. The legislation increased the statutory cap from $30 million to $40 million for life sciences tax incentives and made targeted reforms to strengthen the program.
The application period for the new MLSC Tax Incentive cycle opens today June 12, 2025, and will close at 5 p.m. on July 16, 2025. Similar to the first round, the awards will be for net new jobs created during calendar year 2025. The second cycle of the MLSC Tax Incentive program will run with the same criteria as the first cycle. Exact details of the program can be found in the updated solicitation on the MLSC website.
This year’s Tax Incentive Program award recipients represent a diverse cohort of companies working on drug discovery and development, medical devices, diagnostics, and manufacturing.
“The Massachusetts Life Sciences Center’s tax-incentive award is more than a financial boost—it’s a vote of confidence in the bold science happening here in the Commonwealth. For Thymmune, it advances our mission to regenerate the human thymus and deliver first-in-class immune-restorative therapies to patients who have no alternatives today,” said Stan Wang, M.D., Ph.D., Founder & CEO of Thymmune Therapeutics. “We’re grateful to Governor Healey, the MLSC, and the Legislature for investing not only in jobs, but in the people and ideas that keep Massachusetts at the forefront of life-science innovation.”
The recipients include:
Company | Expansion Location | Incentive Amount | Job Commitment |
Alnylam Pharmaceuticals Inc. | Norton | $1,840,000 | 100 |
Argenx Us Inc. | Boston | $1,080,000 | 60 |
Amplitude Vascular Systems Inc. | Boston | $245,000 | 10 |
Novo Nordisk/(Dicerna) | Lexington | $900,000 | 50 |
EyePoint | Northbridge | $365,000 | 15 |
Fresenius Kabi Compounding LLC (Fagron Sterile) | Canton | $420,000 | 20 |
GlaxoSmithKline LLC (GSK) | Cambridge | $2,700,000 | 150 |
Hillstar Bio Inc. | Boston | $115,000 | 5 |
Werfen | Bedford | $1,675,000 | 85 |
Insulet Corporation | Acton | $1,524,000 | 83 |
Integra LifeSciences Corporation | Braintree | $1,997,000 | 89 |
Invagen Pharmaceuticals Inc., wholly owned subsidiary of Cipla Limited | Fall River | $1,795,000 | 70 |
Kailera Therapeutics Inc. | Waltham | $900,000 | 50 |
Lila Sciences Inc. | Cambridge | $1,850,000 | 100 |
Merida Biosciences Inc. | Cambridge | $388,000 | 16 |
NanoDx Inc. | Southborough | $168,000 | 6 |
Nova Biomedical Corporation | Waltham | $1,675,000 | 75 |
Novartis Institutes for BioMedical Research Inc. | Boston | $1,260,000 | 70 |
Parabilis Medicines Inc. | Cambridge | $272,000 | 14 |
PathAI Inc. | Boston | $180,000 | 10 |
QurAlis Corporation | Cambridge | $118,000 | 6 |
Ratio Therapeutics Inc. | Boston | $306,000 | 17 |
Remix Therapeutics Inc. | Watertown | $180,000 | 10 |
RevBio Inc. | Lowell | $150,000 | 5 |
Sharp Sterile Manufacturing LLC | Lee | $125,000 | 5 |
STC Biologics Inc. | Newton | $186,000 | 7 |
Superluminal Medicines Inc. | Boston | $437,000 | 19 |
Thymmune Therapeutics Inc. | Cambridge | $135,000 | 5 |
Topo Therapeutics Inc. | Watertown | $161,000 | 7 |
Tscan Therapeutics Inc. | Waltham | $470,000 | 25 |
Vertex Pharmaceuticals Inc. | Boston | $5,610,000 | 300 |
Viridian Therapeutics Inc. | Waltham | $465,000 | 25 |
ZOLL Medical Corporation | Chelmsford | $210,000 | 10 |
The MLSC jointly administers the Tax Incentive Program with the Massachusetts Department of Revenue, which oversees the technical administration of the incentives. Awardees are required to maintain job commitments over a three-year period. The program includes regular reporting requirements for awardees to document jobs created as a result of the incentive. The MLSC has continued to use the Tax Incentive Program to leverage diverse life sciences assets across Massachusetts and encourage growth, expansion, and retention on a statewide basis.
沒有留言:
發佈留言